Sobi to present new interim ASPIRE data at EAHAD congress suggesting that patients can reduce bleeding rates with long-term Elocta treatment

New interim results from ASPIRE, the ongoing long-term extension study of Elocta® (efmoroctocog alfa), marketed by Biogen as Eloctate® (Antihemophilic Factor (Recombinant), Fc Fusion Protein) in the United States, suggest that patients can maintain prolonged protection against bleeding episodes at extended prophylactic dosing intervals. The data will be presented by Swedish Orphan Biovitrum AB (publ) (Sobi)

and Biogen

at the 9th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), taking place in Malmö, Sweden, 3-5 February, 2016.  In total 13 posters will be presented by the two companies, including results from a European retrospective study of the current treatment practices of haemophilia A and B which emphasises the need for additional innovation in haemophilia. Further data will be presented that show how Elocta may improve joint health in people with haemophilia A. "The interim data from our long-term Elocta extension study, ASPIRE, show that the overall annualised bleeding rates were maintained or even further reduced with long-term prophylactic treatment compared to the rates seen in the pivotal studies", said Dr Krassimir Mitchev, MD, PhD, Vice President, Medical Therapeutic Area Head Haemophilia at Sobi. "In addition, the results of